secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001326190-23-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports Q1 net loss $20.1M; pemvidutide NASH trial initiation mid-2023
--------------------------------------------------------------------------------

- Net loss of $20.1M ($0.40/share) vs $19.4M ($0.44/share) in Q1 2022; R&D expenses $17.2M.
- Cash $165.8M at March 31, 2023; MOMENTUM obesity trial 48-week top-line results expected Q4 2023.
- Pemvidutide 24-week data: 10.7% (2.4mg) and 9.4% (1.8mg) mean weight loss; ~50% achieved ≥10% loss.
- IMPACT Phase 2b NASH trial (~190 subjects) to start mid-2023; top-line results expected Q1 2025.
- HepTcell Phase 2 CHB trial fully enrolled (~80 subjects); top-line results expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/0001326190-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000025/alt-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer